Peptide Composition for Skin Repigmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vitiligo, such as topical corticosteroids and MIA inhibitor peptides, are not sufficiently effective for repigmentation, and there is a need for more therapeutic alternatives to address the selective loss of melanocytes and resulting skin depigmentation.
Innovation Solution
A composition comprising a MIA inhibitor peptide, combined with additional peptides like those of SEQ ID NO: 50, 51, or Pro-Pro, and a pharmaceutically acceptable excipient, which is applied topically to promote skin repigmentation through synergistic effects, enhancing melanin production in vitiligo treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MIA inhibitor peptides are used alone for vitiligo treatment, then some repigmentation effect is achieved, but the effectiveness is insufficient
Solution Approach 1:
The patent combines MIA inhibitor peptides with other peptides (such as those of SEQ ID NO: 50, 51, or Pro-Pro) to create a composite therapeutic composition. This merging of multiple peptide components works synergistically to enhance melanin production and repigmentation effectiveness beyond what single peptides can achieve alone, directly addressing the insufficiency of MIA inhibitor monotherapy.
2Reliability
If combination therapy with multiple peptides is used, then repigmentation effectiveness is improved, but treatment complexity increases
Solution Approach 1:
The patent employs composite peptide materials by formulating MIA inhibitor peptides together with other bioactive peptides in specific combinations. This composite approach creates a synergistic therapeutic composition where the combined peptides work together to enhance melanocyte function and repigmentation, achieving superior clinical effectiveness while the complexity is managed through rational formulation design.
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to a composition for skin repigmentation comprising a peptide inhibitor of MIA (melanoma inhibitory activity) protein, at least an additional peptide, and a pharmaceutically acceptable excipient. The invention also relates to the use of the composition for the prevention and/or treatment of vitiligo. The invention also relates to the cosmetic use of the composition for the repigmentation of skin.